nach oben

Erschienen in:

17.04.2019 | Original Article

Influence of XRCC4 expression by breast cancer cells on ipsilateral recurrence after breast-conserving therapy

verfasst von: Mio Kitagawa, MD, Masanori Someya, MD, PhD, Tomokazu Hasegawa, MD, PhD, Toshihiko Mikami, MD, PhD, Kazuaki Asaishi, MD, PhD, Tadashi Hasegawa, MD, PhD, Yoshihisa Matsumoto, PhD, Goro Kutomi, MD, PhD, Ichiro Takemasa, MD, PhD, Koh-ichi Sakata, MD, PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

We examined the expression of nonhomologous end-joining (NHEJ) proteins by breast cancer cells in patients with or without ipsilateral breast tumor recurrence (IBTR) after breast-conserving therapy. We also investigated whether there was a difference of NHEJ-related protein expression by tumor cells between two types of IBTR, i.e., true recurrence (TR) with regrowth from the tumor bed or development of a new primary tumor (NP).

Patients and methods

The original cohort comprised 560 breast cancer patients who received breast-conserving therapy between February 1995 and March 2006, including 520 patients without IBTR and 40 patients with IBTR. Propensity score matching was employed to select 40 trios (120 patients) consisting of 1 patient with IBTR and 2 patients without IBTR. Immunohistochemical examination of proteins related to NHEJ was performed in surgical specimens.

Results

The 40 patients with IBTR included 22 patients who developed TR and 18 who had NP. The 15-year overall survival rate was 85.9% for patients with NP and 95.5% for those with TR, while it was 96.5% for patients without IBTR. Patients with high XRCC4 expression in tumor cells had significantly higher IBTR rates than those with low XRCC4 expression (P < 0.001). The frequency of TR was significantly higher in patients with high expression of XRCC4 than in those with low XRCC4 expression (p < 0.001). XRCC4 expression by tumor cells was not significantly related to development of NP.

Conclusion

IBTR due to TR may be related to low radiosensitivity of tumor cells, possibly related to high XRCC4 expression.

Nur mit Berechtigung zugänglich

Darby S, McGale P, Correa C et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomized trials. Lancet 378(9804):1707–1716CrossRefPubMed

Wapnir IL, Anderson SJ, Mamounas EP et al (2009) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24(13):2028–2037CrossRef

Oouchi A, Sakata K, Masuoka H et al (2009) The treatment outcome of patients undergoing breast-conserving therapy: the clinical role of postoperative radiotherapy. Breast Cancer 16(1):49–57CrossRefPubMed

Yoshida T, Takei H, Kurosumi M et al (2010) True recurrences and new primary tumors have different clinical features in invasive breast cancer patients with ipsilateral breast tumor relapse after breast-conserving treatment. Breast J 16(2):127–133CrossRefPubMed

Ishitobi M, Ohsumi S, Inaji H et al (2012) Ipsilateral breast tumor recurrence (IBTR) in patients with operable breast cancer who undergo breast-conserving treatment after receiving neoadjuvant chemotherapy: risk factors of IBTR and validation of the MD Anderson Prognostic Index. Cancer 118(18):4385–4393CrossRefPubMed

Veronesi U, Marubini E, Del Vecchio M et al (1995) Local recurrences and distant metastases after conservative breast cancer treatments: partly independent events. J Natl Cancer Inst 87(1):19–27CrossRefPubMed

Panet-Raymond V, Truong PT, McDonald RE et al (2011) True recurrence versus new primary: an analysis of ipsilateral breast tumor recurrences after breast-conserving therapy. Int J Radiat Oncol Biol Phys 81(2):409–417CrossRefPubMed

Hall EJ (2006) DNA strand breaks and chromosomal aberrations. In: Hall EJ, Giaccia AM (eds) Radiobiology for the Radiologist, 6th edn. Lippincott Williams & Wilkins, Philadelphia, pp 16–29

Polo SE, Jackson SP (2011) Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modification. Genes Dev 25:409–433CrossRefPubMedPubMedCentral

10.

Li Z, Otevrel T, Gao Y et al (1995) The XRCC4 gene encodes a novel protein involved in DNA double-strand break repair and V(D)J recombination. Cell 83(7):1079–1089CrossRefPubMed

11.

Bryans M, Valenzano MC, Stamato TD (1999) Absence of DNA ligase IV protein in XR-1 cells: evidence for stabilization by XRCC4. Mutat Res 433(1):53–58CrossRefPubMed

12.

Berg E, Christensen MO, Dalla RI et al (2011) XRCC4 controls nuclear import and distribution of Ligase IV and exchanges faster at damaged DNA in complex with Ligase IV. Dna Repair (Amst) 10(12):1232–1242CrossRef

13.

Iles N, Rulten S, El-Khamisy SF, Caldecott KW (2007) APLF (C2orf13) is a novel human protein involved in the cellular response to chromosomal DNA strand breaks. Mol Cell Biol 27(10):3793–3803CrossRefPubMedPubMedCentral

14.

Jeggo PA (1998) Identification of genes involved in repair of DNA double strand-breaks in mammalian cells. Radiat Res 150:S80–S91CrossRefPubMed

15.

Söderlund Leifler K, Queseth S, Fornander T et al (2010) Low expression of Ku70/80, but high expression of DNA-PKcs, predict good response to radiotherapy in early breast cancer. Int J Oncol 37(6):1547–1554PubMed

16.

Sakata K, Matsumoto Y, Tauchi H et al (2001) Expression of genes involved in repair of DNA double-strand breaks in normal and tumor tissues. Int J Radiat Oncol Biol Phys 49(1):161–167CrossRefPubMed

17.

Kamdar RP, Matsumoto Y (2010) Radiation-induced XRCC4 association with chromatin DNA analyzed by biochemical fractionation. J Radiat Res 51:303–313CrossRefPubMed

18.

Kanda Y (2013) Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMed

19.

Jobsen J, van der Palen J, Riemersma S et al (2014) Pattern of ipsilateral breast tumor recurrence after breast-conserving therapy. Int J Radiat Oncol Biol Phys 89(5):1006–1014CrossRefPubMed

20.

Sjöström M, Lundstedt D, Hartman L et al (2017) Response to radiotherapy after breast-conserving surgery in different breast cancer subtypes in the Swedish breast cancer group 91 radiotherapy randomized clinical trial. J Clin Oncol 35(28):3222–3229CrossRefPubMed

21.

della Rovere GQ, Benson JR (2002) Ipsilateral local recurrence of breast cancer: determinant or indicator of poor prognosis? Lancet Oncol 3(3):183–187CrossRefPubMed

22.

Gieni M, Avram R, Dickson L et al (2012) Local breast cancer recurrence after mastectomy and immediate breast reconstruction for invasive cancer: a meta-analysis. Breast 21(3):230–236CrossRefPubMed

23.

Schnitt SJ (2003) Risk factors for local recurrence in patients with invasive breast cancer and negative surgical margins of excision. Where are we and where are we going? Am J Clin Pathol 120(4):485–488CrossRefPubMed

24.

van der Leij F, Elkhuizen PH, Bartelink H et al (2012) Predictive factors for local recurrence in breast cancer. Semin Radiat Oncol 22(2):100–107CrossRefPubMed

25.

Hayashi J, Sakata KI, Someya M et al (2012) Analysis and results of Ku and XRCC4 expression in hypopharyngeal cancer tissues treated with chemoradiotherapy. Oncol Lett 4(1):151–155CrossRefPubMedPubMedCentral

26.

Hori M, Someya M, Sakata KI et al (2017) Influence of XRCC4 expression in esophageal cancer cells on the response to radiotherapy. Med Mol Morphol 50(1):25–33CrossRefPubMed

27.

Takada Y, Someya M, Sakata KI et al (2016) Influence of Ku86 and XRCC4 expression in uterine cervical cancer on the response to preoperative radiotherapy. Med Mol Morphol 49(4):210–216CrossRefPubMed

28.

Hada M, Kwok RP (2014) Regulation of ku70-bax complex in cells. J Cell Death 7:11–13CrossRefPubMedPubMedCentral

29.

Sui H, Zhou M, Imamichi H et al (2017) STING is an essential mediator of the Ku70-mediated production of IFN-λ1 in response to exogenous DNA. Sci Signal. https://doi.org/10.1126/scisignal.aah5054 CrossRefPubMed

Titel: Influence of XRCC4 expression by breast cancer cells on ipsilateral recurrence after breast-conserving therapy
verfasst von: Mio Kitagawa, MD
Masanori Someya, MD, PhD
Tomokazu Hasegawa, MD, PhD
Toshihiko Mikami, MD, PhD
Kazuaki Asaishi, MD, PhD
Tadashi Hasegawa, MD, PhD
Yoshihisa Matsumoto, PhD
Goro Kutomi, MD, PhD
Ichiro Takemasa, MD, PhD
Koh-ichi Sakata, MD, PhD
Publikationsdatum: 17.04.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 7/2019
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-019-01468-z

Springer Medizin

Influence of XRCC4 expression by breast cancer cells on ipsilateral recurrence after breast-conserving therapy